Pancreatic Cancer - Pipeline Review, H2 2012

Print Share

Dec 10, 2012 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/q8pp3z/pancreatic_cancer) has announced the addition of Global Markets Direct's new report "Pancreatic Cancer - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Pancreatic Cancer. - A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pancreatic Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Pancreatic Cancer Therapeutics Development Include: - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Genentech, Inc. - Biotest AG - AbGenomics International, Inc. - Oxford BioMedica plc - Infinity Pharmaceuticals, Inc. - YM BioSciences Inc. - FibroGen, Inc. - Light Sciences Oncology, Inc. - Piramal Healthcare Limited - MediGene AG And many more... For more information visit http://www.researchandmarkets.com/research/q8pp3z/pancreatic_cancer Source: Global Markets Direct

CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Oncology (http://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=q8pp3z)

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

(C)1994-2012 M2 COMMUNICATIONS

**********************************************************************

As of Thursday, 12-06-2012 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated a DOWNTREND on
02-15-2012 for AZN @ $45.43.

As of Thursday, 12-06-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated an UPTREND on
03-13-2012 for BMY @ $33.26.

As of Thursday, 12-06-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated a DOWNTREND on
05-17-2012 for GSK @ $44.67.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2012 Comtex News Network, Inc. All rights reserved.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.